Literature DB >> 20425034

The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders.

Arash Velayati1, W Haung Yu, Ellen Sidransky.   

Abstract

Mutations in the gene encoding glucocerebrosidase (GBA), the enzyme deficient in the lysosomal storage disorder Gaucher disease, are associated with the development of Parkinson disease and other Lewy body disorders. In fact, GBA variants are currently the most common genetic risk factor associated with parkinsonism, and identified subjects with Parkinson disease are more than five times more likely to carry mutations in GBA. The mechanisms underlying this association are not known, but proposed theories include enhanced protein aggregation, alterations in lipid levels, and autophagy-lysosomal dysfunction promoting the retention of undegraded proteins. We review the genetic studies linking GBA to parkinsonism, as well as several of the mechanisms postulated to explain the association of GBA mutations and the synucleinopathies, which demonstrate how studies of a rare mendelian disease may provide insights into our understanding of a common complex disorder.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20425034      PMCID: PMC3529411          DOI: 10.1007/s11910-010-0102-x

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  78 in total

1.  Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela.

Authors:  Michael J Eblan; Joann Nguyen; Shira G Ziegler; Alicia Lwin; Melissa Hanson; Marisol Gallardo; Roberto Weiser; Marisel De Lucca; Andrew Singleton; Ellen Sidransky
Journal:  Mov Disord       Date:  2006-02       Impact factor: 10.338

2.  Increased incidence of Parkinson disease among relatives of patients with Gaucher disease.

Authors:  Assaf Halperin; Deborah Elstein; Ari Zimran
Journal:  Blood Cells Mol Dis       Date:  2006-05-02       Impact factor: 3.039

3.  Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice.

Authors:  Taichi Hara; Kenji Nakamura; Makoto Matsui; Akitsugu Yamamoto; Yohko Nakahara; Rika Suzuki-Migishima; Minesuke Yokoyama; Kenji Mishima; Ichiro Saito; Hideyuki Okano; Noboru Mizushima
Journal:  Nature       Date:  2006-04-19       Impact factor: 49.962

4.  Phosphatidylserine in addition to phosphatidylethanolamine is an in vitro target of the mammalian Atg8 modifiers, LC3, GABARAP, and GATE-16.

Authors:  Yu-shin Sou; Isei Tanida; Masaaki Komatsu; Takashi Ueno; Eiki Kominami
Journal:  J Biol Chem       Date:  2005-11-22       Impact factor: 5.157

5.  Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles.

Authors:  Anu R Sawkar; Sara L Adamski-Werner; Wei-Chieh Cheng; Chi-Huey Wong; Ernest Beutler; Klaus-Peter Zimmer; Jeffery W Kelly
Journal:  Chem Biol       Date:  2005-11

6.  ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity.

Authors:  Idit Ron; Mia Horowitz
Journal:  Hum Mol Genet       Date:  2005-07-06       Impact factor: 6.150

7.  Divergent phenotypes in Gaucher disease implicate the role of modifiers.

Authors:  O Goker-Alpan; K S Hruska; E Orvisky; P S Kishnani; B K Stubblefield; R Schiffmann; E Sidransky
Journal:  J Med Genet       Date:  2005-06       Impact factor: 6.318

8.  Mutation analysis of Gaucher disease patients in Taiwan: high prevalence of the RecNciI and L444P mutations.

Authors:  Lei Wan; Chin-Moo Hsu; Chang-Hai Tsai; Cheng-Chun Lee; Wuh-Liang Hwu; Fuu-Jen Tsai
Journal:  Blood Cells Mol Dis       Date:  2006-03-20       Impact factor: 3.039

9.  Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population.

Authors:  M Toft; L Pielsticker; O A Ross; J O Aasly; M J Farrer
Journal:  Neurology       Date:  2006-02-14       Impact factor: 9.910

Review 10.  Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.

Authors:  I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada
Journal:  Neurology       Date:  2005-10-19       Impact factor: 9.910

View more
  57 in total

Review 1.  Recent advances in the genetics of Parkinson's disease.

Authors:  Ian Martin; Valina L Dawson; Ted M Dawson
Journal:  Annu Rev Genomics Hum Genet       Date:  2011       Impact factor: 8.929

2.  Adamantyl glycosphingolipids provide a new approach to the selective regulation of cellular glycosphingolipid metabolism.

Authors:  Mustafa Kamani; Murugesapillai Mylvaganam; Robert Tian; Brigitte Rigat; Beth Binnington; Clifford Lingwood
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

Review 3.  Glycosphingolipid functions.

Authors:  Clifford A Lingwood
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

Review 4.  The pathophysiology of GD - current understanding and rationale for existing and emerging therapeutic approaches.

Authors:  Derralynn A Hughes; Gregory M Pastores
Journal:  Wien Med Wochenschr       Date:  2010-12

Review 5.  The role of dopamine in the pathogenesis of GBA1-linked Parkinson's disease.

Authors:  Lena F Burbulla; Dimitri Krainc
Journal:  Neurobiol Dis       Date:  2019-07-25       Impact factor: 5.996

6.  CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy.

Authors:  S Pablo Sardi; Jennifer Clarke; Cathrine Kinnecom; Thomas J Tamsett; Lingyun Li; Lisa M Stanek; Marco A Passini; Gregory A Grabowski; Michael G Schlossmacher; Richard L Sidman; Seng H Cheng; Lamya S Shihabuddin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-05       Impact factor: 11.205

7.  A twelve-year follow-up study on a case of early-onset parkinsonism preceding clinical manifestation of Gaucher disease.

Authors:  Maciej Machaczka; Martin Paucar Arce; Malgorzata Rucinska; Takashi Yoshitake; Jan Kehr; Wojciech Jurczak; Aleksander B Skotnicki; Jan-Erik Månsson; Anna Tylki-Szymanska; Per Svenningsson
Journal:  JIMD Rep       Date:  2011-09-20

8.  Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.

Authors:  Thai Leong Yap; James M Gruschus; Arash Velayati; Wendy Westbroek; Ehud Goldin; Nima Moaven; Ellen Sidransky; Jennifer C Lee
Journal:  J Biol Chem       Date:  2011-06-08       Impact factor: 5.157

Review 9.  Cerebrospinal fluid biomarkers in Parkinson disease.

Authors:  Lucilla Parnetti; Anna Castrioto; Davide Chiasserini; Emanuele Persichetti; Nicola Tambasco; Omar El-Agnaf; Paolo Calabresi
Journal:  Nat Rev Neurol       Date:  2013-02-19       Impact factor: 42.937

Review 10.  The neurogenetics of atypical parkinsonian disorders.

Authors:  Brent L Fogel; Mary C Clark; Daniel H Geschwind
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.